Article
Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Infectious diseases (London, England) - 1 Mar 2020
Vizcarra Pilar, Blanco José L, Montejano Rocío, Negredo Eugenia, Espinosa Nuria, Casado José L
Abstract excerpt
Background: Little is known about the impact of baseline resistance-associated mutations (RAMs) on the outcomes of alternative therapeutic strategies such as dual regimens. We assessed the efficacy of boosted darunavir plus raltegravir (DRV + RAL) dual regimen as a simplification strategy in virologically suppressed patients with protease inhibitors RAMs.Methods: Retrospective, multicentre study on the evolution...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.